Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
EV to Sales: Discounted Valuation
Trending lower, below historical average, structural decline.
Left:
||||
Enterprise value to sales ratio
Latest
6.03
↓ 94% below average
Average (9y)
96.19
Historical baseline
Range
High:304.42
Low:6.03
CAGR
-27.9%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | 6.03 | -65.3% |
| 2023 | 17.41 | +33.9% |
| 2022 | 13.00 | -85.5% |
| 2021 | 89.86 | -70.5% |
| 2020 | 304.42 | +259.4% |
| 2019 | 84.71 | +27.4% |
| 2018 | 66.50 | -43.5% |
| 2017 | 117.64 | -20.5% |
| 2016 | 147.96 | +29.4% |
| 2015 | 114.32 | - |